|drug1518||Favipiravir Combined With Tocilizumab Wiki||1.00|
|drug3738||Standard of care Wiki||0.20|
|D014777||Virus Diseases NIH||0.11|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
A randomized controlled trial on using Ivermectin and doxycycline to treat mild-moderate outpatients, severe, and critical inpatients of Coronavirus disease 19 (COVID-19) along with standard of care. Seventy Iraqi COVID-19 patients received Ivermectin and Doxycycline plus standard of care versus seventy Iraqi COVID-19 patients received standard of care only. .
Description: The effect of the experimental drugs to reduce the mortality rate (death rate) of treated patientsMeasure: Mortality rate Time: Up to 8 weeks
Description: rate of patients under treatment who undergo progression of disease to a more advanced stageMeasure: Rate of progression disease Time: up to 8 weeks
Description: time needed by treated patients to recover (become symptoms free and polymerase chain reaction, or PCR, negative)Measure: Time to recovery Time: Up to 8 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports